Abstract
Cancer patients often exhibit immunosuppression that is caused by the expanding tumor mass. This fact has severely compromised many efforts to develop effective cancer vaccines in the past. However, a new generation of immunotherapies takes focus on both activating the effector cells of the immune system as well as reverting the immunosuppression. This two-step process has lead to impressive anti-tumor effects both in experimental settings as well as in initial clinical trials. With new and powerful techniques for genetic engineering, the transfer of immunostimulating genes has gained interest. Genetic engineering of the tumor micromilieu has, for example, shown to be an effective means for breaking tumor-induced immunosuppression in an experimental model of bladder cancer. Genetic engineering can also be used to modify the immune effector cells to efficiently target tumor cells and to simultaneously resist immune inhibition. This review will discuss the immunological status of cancer patients with focus on T regulatory cells and their inhibitory cytokines as well as offer a survey of novel immune strategies for cancer gene therapy.
Keywords: Gene therapy, cancer vaccine, genetic engineering, immunotherapy, DC vaccine, T regulatory cells
Current Cancer Therapy Reviews
Title: Genetic Engineering - A New Era for Cancer Immunotherapy?
Volume: 3 Issue: 3
Author(s): Angelica Loskog and Thomas H. Totterman
Affiliation:
Keywords: Gene therapy, cancer vaccine, genetic engineering, immunotherapy, DC vaccine, T regulatory cells
Abstract: Cancer patients often exhibit immunosuppression that is caused by the expanding tumor mass. This fact has severely compromised many efforts to develop effective cancer vaccines in the past. However, a new generation of immunotherapies takes focus on both activating the effector cells of the immune system as well as reverting the immunosuppression. This two-step process has lead to impressive anti-tumor effects both in experimental settings as well as in initial clinical trials. With new and powerful techniques for genetic engineering, the transfer of immunostimulating genes has gained interest. Genetic engineering of the tumor micromilieu has, for example, shown to be an effective means for breaking tumor-induced immunosuppression in an experimental model of bladder cancer. Genetic engineering can also be used to modify the immune effector cells to efficiently target tumor cells and to simultaneously resist immune inhibition. This review will discuss the immunological status of cancer patients with focus on T regulatory cells and their inhibitory cytokines as well as offer a survey of novel immune strategies for cancer gene therapy.
Export Options
About this article
Cite this article as:
Angelica Loskog and Thomas H. Totterman , Genetic Engineering - A New Era for Cancer Immunotherapy?, Current Cancer Therapy Reviews 2007; 3 (3) . https://dx.doi.org/10.2174/157339407781368341
DOI https://dx.doi.org/10.2174/157339407781368341 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Advancements in Lipid Nanoparticle Delivery Systems for mRNA Therapeutics
The thematic issue will focus on key areas such as lipid nanoparticles, mRNA therapeutics, drug delivery systems, nanotechnology in medicine, targeted therapy, non-viral vectors, precision medicine, and biomedical engineering.read more
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Application of dsRNA in Cancer Immunotherapy: Current Status and Future Trends
Anti-Cancer Agents in Medicinal Chemistry Type 2 Diabetes Mellitus and the Elderly: An Update on Drugs Used to Treat Glycaemia
Current Vascular Pharmacology The Design and Synthesis of Novel Phenothiazine Derivatives as Potential Cytotoxic Agents
Letters in Drug Design & Discovery Point of NO Return for Nitrergic Nerves in Diabetes: A New Insight into Diabetic Complications
Current Pharmaceutical Design Chemical and Radiochemical Considerations in Radiolabeling with α-Emitting Radionuclides
Current Radiopharmaceuticals Identification of Phosphoproteins and their Impact as Biomarkers in Cancer Therapeutics
Current Signal Transduction Therapy Genetic Variations in Telomere Maintenance, with Implications on Tissue Renewal Capacity and Chronic Disease Pathologies
Current Pharmacogenomics and Personalized Medicine PET Imaging with [<sup>68</sup>Ga]NOTA-RGD for Prostate Cancer: A Comparative Study with [<sup>18</sup>F]Fluorodeoxyglucose and [<sup>18</sup>F]Fluoroethylcholine
Current Cancer Drug Targets Assessment of a Synthetic Steroid and Flutamide on Dopamine, GSH and H<sub>2</sub>O<sub>2</sub> Levels in Rat Brain in Presence of Fructose
Endocrine, Metabolic & Immune Disorders - Drug Targets Oxidative Stress, Pro-Inflammatory Cytokines, and Antioxidants Regulate Expression Levels of MicroRNAs in Parkinson’s Disease
Current Aging Science Treatment of Chronic Pain with Drugs that Modulate Central Nervous System Serotonin and Norepinephrine
Current Drug Therapy Optimizing Antitumor Efficacy and Adverse Effects of Pegylated Liposomal Doxorubicin by Scheduled Plasmapheresis: Impact of Timing and Dosing
Current Drug Delivery TNFα Modulation of Visceral and Spinal Sensory Processing
Current Pharmaceutical Design Metabolic Targeting of Cancers: From Molecular Mechanisms to Therapeutic Strategies
Current Medicinal Chemistry The Targets of Curcumin
Current Drug Targets Nutritional Targeting of Cyclooxygenase-2 for Colon Cancer Prevention
Inflammation & Allergy - Drug Targets (Discontinued) Interrelationships Among Gut Microbiota and Host: Paradigms, Role in Neurodegenerative Diseases and Future Prospects
CNS & Neurological Disorders - Drug Targets DLX6-AS1: An Indispensable Cancer-related Long Non-coding RNA
Current Pharmaceutical Design Tankyrases: Structure, Function and Therapeutic Implications in Cancer
Current Pharmaceutical Design Histone Deacetylase Inhibitors in Cancer Treatment: A Review of the Clinical Toxicity and the Modulation of Gene Expression in Cancer Cells
Current Pharmaceutical Biotechnology